Baseline Investigation of Patients With Cardiac Arrest in China (BASIC)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03926325 |
Recruitment Status :
Not yet recruiting
First Posted : April 24, 2019
Last Update Posted : April 30, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Cardiac Arrest |
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 100000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Target Follow-Up Duration: | 1 Year |
Official Title: | Baseline Investigation of Patients With Cardiac Arrest in China |
Estimated Study Start Date : | May 1, 2019 |
Estimated Primary Completion Date : | June 30, 2022 |
Estimated Study Completion Date : | December 31, 2022 |

- incidence of OHCA treated by EMS [ Time Frame: Latest data inclusion June 30, 2022 ]
- incidence of IHCA [ Time Frame: Latest data inclusion June 30, 2022 ]
- survival to hospital discharge or 30d survival of OHCA [ Time Frame: at hospital discharge, 30days after cardiac arrest occurs ]
- survival to hospital discharge or 30d survival of IHCA [ Time Frame: at hospital discharge, 30days after cardiac arrest occurs ]
- prevalence of favorable neurological outcome after cardiac arrest according to Cerebral Performance Category (CPC) Scale [ Time Frame: at hospital discharge, 30days after cardiac arrest occurs ]CPC 1 and 2 as a favorable neurological outcome; CPC 1, Good Cerebral Performance; CPC 2, Moderate Cerebral Disability; CPC 3, Severe Cerebral Disability; CPC 4, Coma, vegetative state; CPC 5, Brain death
- survival of OHCA [ Time Frame: 6 months and 1 year after cardiac arrest occurs ]
- survival of IHCA [ Time Frame: 6 months and 1 year after cardiac arrest occurs ]
- prevalence of favorable neurological outcome after cardiac arrest according to Cerebral Performance Category (CPC) Scale [ Time Frame: 6 months and 1 year after cardiac arrest occurs ]CPC 1 and 2 as a favorable neurological outcome; CPC 1, Good Cerebral Performance; CPC 2, Moderate Cerebral Disability; CPC 3, Severe Cerebral Disability; CPC 4, Coma, vegetative state; CPC 5, Brain death
- rate of return of spontaneous circulation [ Time Frame: Latest data inclusion June 30,2022 ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- OHCA: Every patient who suffered a cardiac arrest that occurred in any location other than a hospital, and was attended and/or treated by an EMS.
- IHCA: Every patient who suffered a cardiac arrest in hospital.
- the representative population-based survey: Every patient who suffered a cardiac arrest in the selected cities or suburbs.
Exclusion Criteria:
- OHCA: 1)The out-of-hospital cardiac arrest patients who were taken to the hospital by their family members; 2) Bystanders suspected cardiac arrest, but the ROSC was achieved without defibrillation or resuscitation by EMS.
- IHCA: The patient who suffered a cardiac arrest that occurred out-of-hospital and then transferred to the hospital.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03926325
Contact: Feng Xu, Dr | +86-18560083066 | xufengsdu@126.com | |
Contact: Chang Pan, Dr | +86-18560082290 | panchang0517@163.com |
China, Shandong | |
Qilu Hospital of Shandong University | |
Jinan, Shandong, China, 250012 | |
Contact: Feng Xu, Dr +86-18560083066 xufengsdu@126.com | |
Contact: Chang Pan, Dr +86-18560082290 panchang0517@163.com | |
Principal Investigator: Feng Xu, Dr |
Principal Investigator: | Feng Xu, Dr | Qilu Hospital of Shandong University |
Responsible Party: | Feng Xu, Director of Emergency Department, Qilu Hospital of Shandong University |
ClinicalTrials.gov Identifier: | NCT03926325 |
Other Study ID Numbers: |
QLEmer201904 |
First Posted: | April 24, 2019 Key Record Dates |
Last Update Posted: | April 30, 2019 |
Last Verified: | April 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Heart Arrest Heart Diseases Cardiovascular Diseases |